Ionis Sets Late-June Olezarsen Launch After FDA Priority Review, 200-Rep Team Ready
Ionis received FDA priority review for its olezarsen sNDA in severe hypertriglyceridemia with a June 30 PDUFA date, targeting a late-June/early-July launch with a fully hired ~200-rep team. TRYNGOLZA posted $108 million in first-year revenue with a 56% quarter-over-quarter gain, driving peak combined FCS/sHTG sales forecasts above $2 billion.
1. FDA Priority Review and Launch Plans
Ionis received FDA acceptance of its supplemental NDA for olezarsen in severe hypertriglyceridemia, securing priority review with a June 30 PDUFA date. This accelerated timeline positions the company to launch the therapy in late June or early July, potentially advancing patient access by up to four months.
2. Commercial Preparations and Field Team
The company has fully hired a ~200-rep U.S. field team and secured commercial supply, while medical affairs has been educating clinicians on severe hypertriglyceridemia and patient identification. Ionis’s prior TRYNGOLZA launch in familial chylomicronemia syndrome has built credibility among lipid specialists and pancreatologists.
3. TRYNGOLZA Performance and Sales Forecasts
TRYNGOLZA generated $108 million in its first year with a 56% quarter-over-quarter revenue increase, surpassing consensus and prompting a raise in peak combined FCS and sHTG sales expectations to over $2 billion. The strong uptake underscores the significant unmet need in severe lipid disorders.
4. 2026 Pipeline Outlook
Ionis expects three product approvals and launches in 2026, including zilganersen for Alexander disease and bepirovirsen for chronic hepatitis B via GSK, alongside potential late-stage readouts for pelacarsen and eplontersen. These milestones reflect Ionis’s evolution into a fully integrated commercial-stage biotechnology company.